Characterization of a rat model of metastatic prostate cancer bone pain

References

• FidlerIJCritical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lectureCancer Res19905019613061381698118
   PubMed Web of Science ®Google Scholar
• GuiseTAKozlowWMHeras-HerzigAMolecular mechanisms of breast cancer metastases to boneClin Breast Cancer20055Suppl 2S46S5315807924
   PubMedGoogle Scholar
• MercadanteSMalignant bone pain: pathophysiology and treatmentPain1997691–21189060007
   PubMed Web of Science ®Google Scholar
• MiaoXRGaoXFWuJXBilateral downregulation of Nav1.8 in dorsal root ganglia of rats with bone cancer pain induced by inoculation with Walker 256 breast tumor cellsBMC Cancer20101021620482896
   PubMed Web of Science ®Google Scholar
• SaadFLiptonABone-marker levels in patients with prostate cancer: potential correlations with outcomesCurr Opin Support Palliat Care20104312713420489645
   PubMedGoogle Scholar
• BagiCMTargeting of therapeutic agents to bone to treat metastatic cancerAdv Drug Deliv Rev2005577995101015876400
   PubMed Web of Science ®Google Scholar
• LandisSHMurrayTBoldenSWingoPACancer statistics, 1999CA Cancer J Clin19994911831
   Web of Science ®Google Scholar
• LiuSYangJWangLTibia tumor-induced cancer pain involves spinal p38 mitogen-activated protein kinase activation via TLR4-dependent mechanismsBrain Res2010134621322320478276
   PubMed Web of Science ®Google Scholar
• ColemanRESkeletal complications of malignancyCancer199780Suppl 8158815949362426
   PubMed Web of Science ®Google Scholar
• CoyleNAdelhardtJFoleyKMPortenoyRKCharacter of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of lifeJ Pain Symptom Manage19905283932348092
   PubMedGoogle Scholar
• FulfaroFCasuccioATicozziCRipamontiCThe role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trialsPain19987831571699870569
   PubMed Web of Science ®Google Scholar
• LiptonABisphosphonates and breast carcinomaCancer199780Suppl 8166816739362434
   PubMed Web of Science ®Google Scholar
• PortenoyRKLesagePManagement of cancer painLancet199935391651695170010335806
   PubMed Web of Science ®Google Scholar
• RosierRBone painAm J Hosp Palliat Care199296371297387
   PubMedGoogle Scholar
• TankoLBKarsdalMAChristiansenCLeemingDJBiochemical approach to the detection and monitoring of metastatic bone disease: what do we know and what questions need answers?Cancer Metastasis Rev200625465966817160557
   PubMed Web of Science ®Google Scholar
• GeisCGraulichMWissmannAEvoked pain behavior and spinal glia activation is dependent on tumor necrosis factor receptor 1 and 2 in a mouse model of bone cancer painNeuroscience2010169146347420417692
   PubMed Web of Science ®Google Scholar
• HaldAHansenRRThomsenMWCancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790Int J Cancer200912551177118519444917
   PubMed Web of Science ®Google Scholar
• MantyhPWClohisyDRKoltzenburgMHuntSPMolecular mechanisms of cancer painNat Rev Cancer20022320120911990856
   PubMed Web of Science ®Google Scholar
• PacharinsakCBeitzAAnimal models of cancer painComp Med200858322023318589864
   PubMed Web of Science ®Google Scholar
• MercadanteSArcuriEBreakthrough pain in cancer patients: pathophysiology and treatmentCancer Treat Rev199824642543210189409
   PubMed Web of Science ®Google Scholar
• PortenoyRKHagenNABreakthrough pain: definition, prevalence and characteristicsPain19904132732811697056
   PubMed Web of Science ®Google Scholar
• PortenoyRKPayneDJacobsenPBreakthrough pain: characteristics and impact in patients with cancer painPain1999811–212913410353500
   PubMed Web of Science ®Google Scholar
• ClohisyDRMantyhPWBone cancer painClin Orthop Relat Res2003415SupplS279S28814600620
   PubMed Web of Science ®Google Scholar
• MercadanteSControversies over spinal treatment in advanced cancer patientsSupport Care Cancer1998664955029833297
   PubMed Web of Science ®Google Scholar
• PortenoyRKManaging cancer pain poorly responsive to systemic opioid therapyOncology (Williston Park)1999135 Suppl 2252910356695
   PubMed Web of Science ®Google Scholar
• SmolevJKHestonWDWScottWWCharacterization of the Dunning R-3327-H prostatic carcinoma: an appropriate animal model for prostatic cancerCan Treat Rep197761273
   PubMedGoogle Scholar
• IssacsJTYuGWCoffeyDSThe characterization of a newly identified, highly metastatic variety of Dunning R3327 rat prostatic adenocarcinoma system: the MATLyLu tumorInvest Urol198119120237251319
   PubMedGoogle Scholar
• LubaroffDMCanfieldLFeldbushTLR3327 adenocarcinoma of the copenhagen rat as a model for the study of the immunologic aspects of prostate cancerJ Natl Cancer Inst197758616771689864747
   PubMedGoogle Scholar
• IsaacsJTHestonWDWWeismannRMAnimal models of hormone sensitive and insensitive prostatic adenocarcinomas: Dunning R-3327-H, R-3327-HI and R-3327-ATCancer Res1978381143534359698976
   PubMed Web of Science ®Google Scholar
• IssacsJTIssacsWBCoffeyDSModels for the development of non-receptor methods for distinguishing androgen sensitive and insensitive prostatic tumorsCancer Res1979392652445468
   PubMed Web of Science ®Google Scholar
• WengerASMickeyDDHallMIn vitro characterization of MATLyLu: a Dunning rat prostate adenocarcinoma tumor sublineJ Urol1984131123212366539387
   PubMed Web of Science ®Google Scholar
• NobleSBalfourJAMeloxicamDrugs19965134244308882380
   PubMed Web of Science ®Google Scholar
• FleischmannRImranISlobodinGMeloxicamExpert Opin Pharmacother20023101501151212387696
   PubMedGoogle Scholar
• EngelhardtGBögelRSchnitzerCMeloxicam: influence on arachidonic acid metabolism. Part I. In vitro findingsBiochem Pharmacol199651121288534264
   PubMed Web of Science ®Google Scholar
• NaruseTNishidaYHosonoKMeloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routesCarcinogenesis200627358459216219634
   PubMed Web of Science ®Google Scholar
• PairetMEngelhardtGThe preferential inhibition of COX-2 by meloxicam is hightly dependent on the structure of the drugEur J Rheumatol Inflamm199524Suppl 3272
   Google Scholar
• EngelhardtGPharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2Br J Rheumatol199635Suppl 14128630636
   PubMedGoogle Scholar
• GoldmanAPWilliamsCSShengHLampsLWMeloxicam inhibits the growth of colorectal cancerCarcinogenesis199819219521999886578
   PubMed Web of Science ®Google Scholar
• TsubouchiYMukaiSKawahitoYYamadaRMeloxicam inhibits the growth of non-small cell lung cancerAnticancer Res2000202867287211062695
   PubMed Web of Science ®Google Scholar
• NiiyamaYKawamataTYamamotoJSB366971, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer painBr J Anaesth2009102225125819038965
   PubMed Web of Science ®Google Scholar
• HaldADingMEgerodKDifferential effects of repeated low dose treatment with the cannabinoid agonist WIN 55,212-2 in experimental models of bone cancer pain and neuropathic painPharmacol Biochem Behav2008911384618611408
   PubMed Web of Science ®Google Scholar
• MedhurstSJWalkerKBowesMA rat model of bone cancer painPain2002961–212914011932069
   PubMed Web of Science ®Google Scholar
• Mao-YingQLZhaoJDongZQA rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cellsBiochem Biophys Res Commun200634541292129816725112
   PubMed Web of Science ®Google Scholar
• BaamondeACurto-ReyesVJuarezLAntihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing miceLife Sci200781867368217692876
   PubMed Web of Science ®Google Scholar
• ZhangRXLiuBLiAInterleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylationNeuroscience200815441533153818554806
   PubMed Web of Science ®Google Scholar